New Delhi, Dec. 19 -- CMR Surgical has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its next-generation robotic surgery system, Versius Plus, marking a major step toward entering the highly competitive U.S. surgical robotics market.

The clearance allows Versius Plus to be used for gallbladder removal (cholecystectomy) procedures and paves the way for a commercial launch in the U.S. planned for 2026. For CMR Surgical, the decision represents a long-awaited milestone as the company expands beyond its strong presence in Europe and other international markets.

Track procedure volumes, adoption trends, and hospital-level insights for robotic and minimally invasive surgeries with our comprehensive Surgical Procedure V...